Prophylactic Use of Chloroquine to Prevent Skin Cancer
- 1 March 1963
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 87 (3), 315-322
- https://doi.org/10.1001/archderm.1963.01590150031006
Abstract
A double-blind study was undertaken in man to determine if chloroquine could inhibit cutaneous carcinogenesis. Via a random sampling technique over 200 tumor prone individuals were placed on chloroquine, 250 mg. per day, or an identical appearing placebo. After 11 months, the patients taking chloroquine, when compared to the placebo group, developed fewer new tumors. This was demonstrated in the total number of new tumors and also in the percentage of individuals developing one or more new tumors. Statistically significant figures were found in the 6-17 month time period; however, the results were not significant at the .05 level at any other time period. The findings from this study suggest that chloroquine may have a moderate suppressive effect upon carcinogenesis.Keywords
This publication has 4 references indexed in Scilit:
- Light Sensitive Eruptions Treated with Atabrine and ChloroquineJournal of Investigative Dermatology, 1954
- RHEUMATOID ARTHRITIS THERAPY - A RATIONALE AND THE USE OF CHLOROQUINE DIPHOSPHATE1953
- METABOLISM OF THE MALARIAL PARASITE, WITH REFERENCE PARTICULARLY TO THE ACTION OF ANTIMALARIAL AGENTS .2. ATABRINE (QUINACRINE) INHIBITION OF GLUCOSE OXIDATION IN PARASITES INITIALLY DEPLETED OF SUBSTRATE - REVERSAL BY ADENYLIC ACID1946
- FLAVOENZYME CATALYSIS - INHIBITION OF D-AMINO ACID OXIDASE BY COMPETITION WITH FLAVIN-ADENINE-DINUCLEOTIDE OF ATABRINE (QUINACRINE), QUININE, AND CERTAIN OTHER COMPOUNDS1946